- Drug Pipelines
- April 2024
- 80 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- September 2023
- 65 Pages
Global
From €6752EUR$6,995USD£5,791GBP
- Report
- February 2021
- 50 Pages
Global
From €2654EUR$2,750USD£2,277GBP
- Report
- August 2022
- 117 Pages
Global
From €4343EUR$4,500USD£3,726GBP
- Report
- January 2019
- 29 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- January 2019
- 18 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- January 2019
- 17 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Drug Pipelines
- January 2019
- 510 Pages
Global
From €21234EUR$22,000USD£18,215GBP
- Report
- July 2020
- 1740 Pages
Global
From €4633EUR$4,800USD£3,974GBP
- Report
- January 2019
- 35 Pages
Global
From €965EUR$1,000USD£828GBP
Zydelig (idelalisib) is a prescription medication used to treat certain types of leukemia. It is a kinase inhibitor, meaning it works by blocking certain proteins that help cancer cells grow and divide. Zydelig is approved for use in adults with chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). It is also approved for use in combination with other medications to treat relapsed small lymphocytic lymphoma (SLL).
Zydelig is manufactured by Gilead Sciences, Inc., a biopharmaceutical company based in California. The drug was approved by the U.S. Food and Drug Administration (FDA) in 2014. It is available in tablet form and is taken orally.
Other companies in the market include Novartis, Celgene, and AbbVie. These companies produce medications for the treatment of leukemia, including targeted therapies, immunotherapies, and chemotherapy. Show Less Read more
